本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Kiniksa Pharmaceuticals Ltd.

34.28
+0.79002.36%
盘后34.500.2200+0.64%19:57 EDT
成交量:54.56万
成交额:1,860.05万
市值:25.40亿
市盈率:519.11
高:34.51
开:33.93
低:33.45
收:33.49
52周最高:34.55
52周最低:17.82
股本:7,410.77万
流通股本:3,355.22万
量比:1.53
换手率:1.63%
股息:- -
股息率:- -
每股收益(TTM):0.0660
每股收益(LYR):-0.6047
净资产收益率:1.03%
总资产收益率:0.46%
市净率:5.13
市盈率(LYR):-56.69

数据加载中...

2024/10/08

重要事件披露

Form 8-K - Current report
2024/09/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

摘牌通告

Form 15-15D/A - Suspension of duty to report [Section 13 and 15(d)]: [Amend]
2024/07/23

重要事件披露

Form 8-K - Current report
2024/07/02

SEC问询函

Form CORRESP - Correspondence
2024/06/28

摘牌通告

Form 15-15D - Suspension of duty to report [Section 13 and 15(d)]
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/25

重要事件披露

Form 8-K - Current report